New Biogen CEO tips subcutaneous lecanemab to help expansion into pre-symptomatic Alzheimer’s

New Biogen CEO Chris Viehbacher has set out plans for a subcutaneous version of lecanemab, outlining how changing the delivery method of the Eisai-partnered Alzheimer’s disease drug could be particularly valuable for pre-symptomatic patients.